Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer commits to rare disease research

Pfizer commits to rare disease research

15th June 2010

Pfizer has created a new research unit which will focus on the treatment of uncommon illnesses affecting fewer than 200,000 patients worldwide.

The pharmaceutical company’s new rare diseases research unit is set to be led by Dr Edward Mascioli and will be dedicated to identifying treatments for the more than 6,000 conditions classified as orphan diseases.

Currently, less than ten per cent of these ailments have treatments which address the underlying causes of the diseases, while investment in these areas of research is typically low.

Dr Jose Carlos Gutierrez-Ramos, senior vice-president of biotherapeutics research and development for Pfizer, said the company’s resources and experience in treating rare illnesses, such as haemophilia, will allow it to become a “driving force” in this area.

He added: “We are hopeful that this research unit will lead to additional new medicines for patients suffering from devastating illnesses for which there is no cure.”

Last month, Pfizer announced the appointment of Dr Mikael Dolsten as the president of its newly-reorganised worldwide research and development unit.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.